期刊
CURRENT OPINION IN CARDIOLOGY
卷 24, 期 1, 页码 50-55出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HCO.0b013e32831bc336
关键词
antiarrhythmia agents; atrium; electrophysiology; fibrillation; potassium current
资金
- Deutsche Stiftung fur Herzforschung
- Canadian Institutes of Health Research
- Mathematics of Information Technology and Complex Systems (MITACS) Network of Centers of Excellence
- Leducq European-North American Atrial Fibrillation Research Alliance (ENAFRA)
- Quebec Heart and Stroke Foundation
Purpose of review Rhythm control remains of therapeutic value for many atrial fibrillation patients despite no evidence of survival benefit. This lack of benefit may relate to side effects of conventional antiarrhythmic drugs. The introduction of novel agents was a logical consequence. Recent findings Novel antiarrhythmics are currently being evaluated in preclinical or clinical studies. Among recently developed drugs, some affect one or more atrial targets, including I-Kur, I-KACh, I-Na or I-SAC, allowing them to act selectively on atria over ventricles. Some drugs that exhibit atrial selectivity have not been successful in preliminary studies. Block of a single atrial-specific target may be insufficient for atrial fibrillation termination and prevention, and multichannel-blocking properties may be a useful alternate approach. Drugs such as vernakalant or ranolazine inhibit multiple channels but display effective and atrial-selective actions. Furthermore, dronedarone, a prototypic multichannel blocker with additional effects on ventricular myocardium, has proven well tolerated and effective in the treatment of atrial fibrillation and may even reduce cardiovascular mortality. Summary Efforts to develop atrial-selective antiarrhythmics are bearing fruit, but such compounds will need to exhibit equal or superior safety and efficacy compared with multichannel blockers such as dronedarone for atrial fibrillation suppression in order to prove their worth. It is still too early to tell whether atrial selectiveness is just hype or truly a hope for antiarrhythmic drug treatment of atrial fibrillation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据